Skip to main content
. Author manuscript; available in PMC: 2013 Mar 22.
Published in final edited form as: Vaccine. 2011 Jul 7;29(38):6485–6497. doi: 10.1016/j.vaccine.2011.06.088

Table 4.

Ongoing randomized phase III trials of prostate cancer immunotherapy

Immunotherapy agent (trial) # of patients Primary endpoint Design Ref.
Ipilimumab 600 OS Chemotherapy-naive; ipilimumab 10 mg/kg IV or placebo (148)
PSA-TRICOM 1200 OS Chemotherapy-naive; vaccine alone or vaccine with adjuvant doses of GM-CSF (46)
Ipilimumab 800 OS Post-docetaxel; ipilimumab 10 mg/kg IV or placebo (149)